Category Archives: Transhuman News

Pick of the day: Dolly: The Sheep That Changed The World

9pm, BBC Two

The Roslin Institute near Edinburgh was once a little-known, no-frills agricultural research centre established to increase post-war food production. That changed when funding was threatened in the 1980s and the institute redirected into genetic engineering, specifically with the aim of finding a cure for cystic fibrosis. And then in 1997, they created a sheep named Dolly, the first mammal to be genetically cloned, and the worlds media came knocking at this quiet corner of Midlothian. This documentary (already shown in Scotland) meets the scientists who worked in secret to crack the holy grail of replicating life.

8pm, ITV

The canine-friendly presenter tries to train an overly eager German shepherd puppy that does not know how or when to calm down. Elsewhere, he works to gain the trust of a terrified West Highland terrier that is too scared to even set foot on the soil outside and works with Battersea staff to encourage the petrified dog to come out of its shell.

9pm, BBC One

Semi-final week continues with the chefs cooking outside the MasterChef kitchen for the first time, opening a pop-up kitchen at a warehouse micro-brewery in the heart of east London. Working on makeshift workstations with limited equipment and no ovens, the semi-finalists must adapt their fine-dining style to impress 14 guests from the culinary world. After that, they return to the studio for a cook-off, serving up a single dish that they hope is good enough to see them join the final line-up.

9pm, Channel 4

Kevin McCloud, Damion Burrows and Michelle Ogundehin visit the final five properties, one of which is added to the shortlist, before the overall winner is announced. This week, they focus on houses that reinvent beloved established types of building, including a 21st-century reboot of the classic Kentish oast, a low-key eco-home in Devon which turns the idea of the country house on its head and a cool contemporary reimagining of the suburban family house in Surrey.

10pm, Sky Documentaries

The docuseries telling the story of Britains 40-year battle with HIV, from the first recorded UK case in 1981 right through to the present day, concludes with a double bill. It begins with a look at how the first government-sponsored national Aids awareness adverts (including that notoriously oblique Dont Die of Ignorance slogan) appeared to cut through some of the prejudice, butthe lack of effective medicine or vaccine hits hard.

10.35pm, BBC One

Highlights of Sunday nights ceremony in Coventry, which acknowledges the best black music in the UK, Africa, the Caribbean and beyond. Dave, the British-Nigerian rapper who topped the charts with his long-awaited second album Were All Alone in This Together, leads the nominations with five, closely followed by drill rapper Central Cee. Theyll both be performing, along with Little Simz, Cleo Sol and Arlo Parks, the singer-songwriter who won this years Mercury Prize.

Theion TVnewsletter is a daily email full of suggestions of what to watch as well as the latest TV news, opinions and interviews.Sign up hereto stay up to date with the best new TV.

Link:
Whats on TV tonight: BBC2 meets the scientists who cloned Dolly the Sheep in 1997 - iNews

Global Next-Generation Biomanufacturing Market to Reach $85. 20 Billion by 2031. Market Report Coverage - Next-Generation Biomanufacturing Market Segmentation.

New York, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Next-Generation Biomanufacturing Market - A Global Analysis: Focus on Single-Use and Digital Platform and Segment Analysis for Workflow, Products, Medical Application, End User, Country Data, and Competitive Landscape - Analysis and Forecast, 2020-2031" - https://www.reportlinker.com/p06189199/?utm_source=GNW

Workflow - Upstream Biomanufacturing and Downstream Biomanufacturing Product - Continuous Upstream Biomanufacturing Products, Single-Use Upstream Biomanufacturing Products, and Downstream Biomanufacturing Products Medical Application - Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Other Applications End User - Biopharmaceutical Companies, CMOs/CDMOs, Research Institutions

Regional Segmentation

North America - U.S. and Canada Europe - U.K., Germany, France, Italy, Spain, Ireland, Switzerland, Russia and Rest-of-Europe Asia Pacific - China, Japan, India, South Korea, Australia, Singapore and Rest-of-Asia-Pacific Latin America - Brazil, Mexico, Argentina and Rest-of-Latin America Rest-of-the-World

Market Growth Drivers

Increasing biologics and biosimilars approvals Growing trend among biomanufacturing vendors to integrate automation technologies Boosting bioproduction workflow while reducing cost, time, and labor

Market Challenges

Complex production steps, process operational complexity, risk of product contamination, maintenance of production efficiency, and validation challenges Lack of skilled professionals Unharmonized manufacturing standards and lack of knowledge and skilled labor in middle-income and low-income countries

Market Opportunities

Increasing development and commercialization of digital bioreactors Increasing Investment in R&D and rapid development of the biopharmaceutical industry

Key Companies Profiled

Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Gurin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd., Solaris Biotechnology Srl., Thermo Fisher Scientific Inc., ZETA GmbH

Key Questions Answered in this Report: What are the key trends of the global next-generation biomanufacturing market? How is the market evolving, and what is its future scope? What is the role of automation in biomanufacturing? What are the major drivers, challenges, and opportunities of the global next-generation biomanufacturing market? What is the regulatory framework of the global next-generation biomanufacturing market? What is the market share of each of the players offering products for next-generation biomanufacturing? What are the key strategies implemented by the major players to sustain the competition of the global next-generation biomanufacturing market? What was the market size of the global next-generation biomanufacturing market in 2020, and what is the anticipated market size in 2031? What is the expected growth rate of the global next-generation biomanufacturing market during the forecast period 2021-2031? What are the different next-generation biomanufacturing products used in the medical field? Which product segment is expected to observe the highest CAGR in the market during the forecast period 2021-2031? What are the key medical applications of the global next-generation biomanufacturing market? Which application type is expected to witness the highest growth rate during the forecast period of 2021-2031? Who are the key end users for the global next-generation biomanufacturing market? What was the market share held by each end user in the global next-generation biomanufacturing market in 2020? What is the expected growth rate and market share by 2031? What was the market value of the leading segments and sub-segments of the global next-generation biomanufacturing market in 2020, and what are the values expected to be in 2031? What are the different macro- and micro-economic factors influencing the growth of the market? Which region dominated the global next-generation biomanufacturing market in 2020? Which geography can be the target market for significant expansion of key companies for different next-generation biomanufacturing products? What are the key countries contributing significantly toward the growth of the next-generation biomanufacturing market? What are the key players of the global next-generation biomanufacturing market, and what is their role in the market? Who are the leading payers in the single-use bioreactor market?

Market Overview

Biomanufacturing is the process of production of commercially important biomolecules by utilizing biological systems for use in medicines, food and beverage processing, and industrial applications.Natural sources such as blood, cultures of microbes, animal cells, or plant cells are often employed to carry out biomanufacturing.

Cells used in the production process can also be derived using genetic engineering techniques.

The research study titled Global Next-Generation Biomanufacturing Market is focused on understanding the key trends of next-generation biomanufacturing with the use of single-use bioreactors and digital bioreactors across the globe.The research study demonstrates the competitive landscape of the global next-generation biomanufacturing market and presents the market dynamics as well as the regulatory framework affecting the growth of the next-generation biomanufacturing across different regions.

The study also presents an in-depth analysis of the drivers, challenges, and opportunities of the market playing a significant role in major countries of North America, Europe, Asia-Pacific, Latin America, and the Rest-of-the-World.

The report is segmented based on workflow and product, medical application, end user, and region, thoroughly represented in different chapters.Each chapter provides a clear understanding of the products existing in the global next-generation biomanufacturing market and the current key trends in each domain.

The chapter further mentions the key companies of each domain and represents their contribution to the market.The report study also provides a holistic view of 15 major companies playing a key role by contributing their next-generation biomanufacturing market products.

In addition, the report covers detailed information on the advent of automation in biomanufacturing with data on types of automation, current trends, and opportunities in the field of automation.

BIS healthcare experts have found global next-generation biomanufacturing to be one of the most rapidly evolving markets. The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to reach a value of $85,201.2 million in 2031.

The following report presents the reader with an opportunity to unlock comprehensive insights regarding the next-generation biomanufacturing market and helps form well-informed strategic decisions. The market research study also offers a broad perspective of the different types of products and services available in the market and their impact on the biomanufacturing industry by providing critical insights into the direction of its future expansion.

Within the research report, the market is segmented based on workflow and product, medical application, end user, and region.Each of these segments has been further categorized into sub-segments to compile an in-depth study.

Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

The global next-generation biomanufacturing market, by workflow, is primarily dominated by upstream biomanufacturing.This is mainly attributed to the involvement of a large number of high-cost equipment in upstream biomanufacturing compared to downstream biomanufacturing.

However, downstream biomanufacturing is expected to witness a high CAGR during the forecast compared to upstream biomanufacturing. This is mainly due to continuous product innovations in the chromatography product lines as well as in filtration systems used in downstream processing.

Among the different regions, North America dominated the global next-generation biomanufacturing market in 2020.Large, well-equipped biomanufacturing facilities with advanced infrastructure and strong investments in the biomanufacturing sector are significantly promoting the growth of the next-generation biomanufacturing market in North America.

Moreover, the ever-expanding biopharmaceuticals and biologics industry in North America is offering huge promises for the industrys growth, attracting the attention of the investors attempting to enter this field. Further, the headquarters of several key industry players in the U.S., such as Thermo Fisher Scientific, Inc., GE Healthcare, PBS Biotech, Inc., CESCO Bioengineering Co. Ltd., and Meissner Filtration Products, Inc., have further strengthened the market in the region.

Among all the regions, Asia-Pacific is expected to witness the highest CAGR during the forecast period 2021-2031.This is mainly attributed to the strong potential of emerging nations of Asia-Pacific, including Japan, India, Australia, South Korea, and Singapore, that are witnessing huge adoption of technologically advanced biomanufacturing equipment.

The growing surge in new capacity installations to meet the increased product demand in developing nations of Asia-Pacific is further expected to boost the next-generation biomanufacturing market growth.

Competitive Landscape

The next-generation biomanufacturing market is largely dominated by companies such as Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Gurin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd, Solaris Biotechnology Srl, Thermo Fisher Scientific Inc., ZETA GmbH. The bioprocess segment of a few companies like GE Healthcare was highly impacted by the COVID-19 pandemic due to the supply-demand gap. Due to this, the company reported low segment revenue in 2020. However, key players like Danaher Corporation witnessed high growth in the revenue attributed to the high demand for bioprocess solutions products.

The global -next-generation biomanufacturing market is growing exponentially due to the high rate of investments from both public and private sectors for the development of facilities equipped with advanced biomanufacturing equipment and instruments.Automation technologies are increasingly gaining prominence in the biomanufacturing industry over the years owing to their vast range of advantages in terms of greater speed, productivity, and accuracy.

Offering a more streamlined and centralized control, the market for automation systems is growing rapidly, with a greater number of companies investing and launching new automation solutions in the market.

Over the past five years, from 2017 to 2021, the next-generation biomanufacturing market has witnessed around 115 key developments biomanufacturing and automation undertaken by key companies that varied from acquisitions to partnerships and collaborations, among others. For instance, in February 2020, Honeywell International Inc. collaborated with Bigfinite, Inc. to contribute to process automation and controls technology with Bigfinites AI, data analytics, and machine learning platform to pace the medical therapies by helping pharma and biotech industries. Further, in March 2019, Rockwell Automation and GE Healthcare underwent a collaborative agreement to combine their automation single-use solution expertise to build bioprocessing operations for digital bioprocessing.

Countries Covered North America U.S. Canada Europe Germany Switzerland Ireland Italy France U.K. Spain Russia Rest-of-Europe Asia-Pacific China India South Korea Japan Australia Singapore Rest-of-Asia-Pacific Latin America Brazil Mexico Argentina Rest-of-Latin America Rest-of-the-WorldRead the full report: https://www.reportlinker.com/p06189199/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read the original:
The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to...

ETF issuer WisdomTree has launched the WisdomTree BioRevolution UCITS ETF (WDNA).

Listed on the London Stock Exchange and Brse Xetra, WDNA seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution ESG Screened Index (WTDNA), and has an expense ratio of 0.45 per cent.The ETF offers access to firms associated with BioRevolution activities through investment in publicly listed companies, which are expected to lead the transformations and advancements in genetics and biotechnology and meet WisdomTrees ESG (environmental, social and governance) criteria.The biology revolution is creating a historic investment opportunity equivalent to the industrial and internet revolutions. says Chris Gannatti, Global Head of Research, WisdomTree. Advancements in biotechnology could represent the greatest innovations of our lifetime. The biology revolution has huge potential to address and mitigate some of the most pressing challenges facing humanity today whether that be climate change, food scarcity or controlling diseases and pandemics. New and transformative innovations could have a profound impact on society and the environment, improving the quality of life for many.WisdomTree leveraged insights from Dr Jamie Metzl, one of the worlds leading technology futurists and Special Strategist for WisdomTree, in its construction of the WisdomTree BioRevolution ESG Screened Index, which identifies the key sectors and industries that are expected to be most significantly transformed by advances in biological science and technology.The genetics and biotechnology revolutions wont just change our healthcare systems, allowing us to live healthier and longer lives, says Dr Jamie Metzl, author of Hacking Darwin: Genetic Engineering and the Future of Humanity. They will also fundamentally transform our world far beyond healthcare. The same technologies driving healthcare innovation will have a seismic impact on industries including agriculture, materials, energy, and information processing, revolutionizing the ways we treat disease, grow food, produce materials, and process data. If the nineteenth was the century of chemistry and the twentieth of physics, the twenty-first will be the century of biology. I am delighted to be collaborating with the amazing team at WisdomTree and uncovering some of the opportunities presented by this historic megatrend.WDNA is the fifth ETF in WisdomTrees thematics UCITS range which also comprises ETFs providing exposure to artificial intelligence, cloud computing, cyber security and battery technology industries. WisdomTrees thematics UCITS range, launched in 2018 with just one product, now has USD1.8 billion in assets under management.Alexis Marinof, Head of Europe, WisdomTree, says: Our approach of partnering with sector experts to construct indices within our thematics product range has resonated with investors and delivered strong investment performance. This approach has contributed to the building of a USD1.8 billion platform of differentiated thematic products which providing transparent and pure sector exposure in an ETF. WDNA brings together all the elements of the biology revolution and is at the sweet spot of innovation and diversification.

Read more from the original source:
WisdomTree expands thematics UCITS range with BioRevolution ETF - ETF Express